Search

Your search keyword '"Prendergast, Aaron"' showing total 31 results
Start Over Author "Prendergast, Aaron"
31 results on '"Prendergast, Aaron"'

1. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Author

Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, and Castellano, Daniel

Published
2023
Full Text
View/download PDF

2. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial

Author

Tan, Wei Shen, Prendergast, Aaron, Ackerman, Charlotte, Yogeswaran, Yathushan, Cresswell, Joanne, Mariappan, Paramananthan, Phull, Jaspal, Hunter-Campbell, Paul, Lazarowicz, Henry, Mishra, Vibhash, Rane, Abhay, Davies, Melissa, Warburton, Hazel, Cooke, Peter, Mostafid, Hugh, Wilby, Daniel, Mills, Robert, Issa, Rami, and Kelly, John D.

Published
2023
Full Text
View/download PDF

3. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Author

Szabados, Bernadett, Kockx, Mark, Assaf, Zoe June, van Dam, Pieter-Jan, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Stanoeva, Diana, Daelemans, Sofie, Rombouts, Miche, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Sharma, Shruti, Aleshin, Alexey, Banchereau, Romain, Castellano, Daniel, and Powles, Thomas

Published
2022
Full Text
View/download PDF

5. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Author

Szabados, Bernadett, Rodriguez-Vida, Alejo, Durán, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez-Vidal, Maria J., Suárez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Mousa, Kelly, Castellano, Daniel, and Powles, Thomas

Published
2021
Full Text
View/download PDF

6. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Author

Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, and Castellano, Daniel

Published
2019
Full Text
View/download PDF

7. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Author

Kocher, Hemant M., Basu, Bristi, Froeling, Fieke E. M., Sarker, Debashis, Slater, Sarah, Carlin, Dominic, deSouza, Nandita M., De Paepe, Katja N., Goulart, Michelle R., Hughes, Christine, Imrali, Ahmet, Roberts, Rhiannon, Pawula, Maria, Houghton, Richard, Lawrence, Cheryl, Yogeswaran, Yathushan, Mousa, Kelly, Coetzee, Carike, Sasieni, Peter, Prendergast, Aaron, and Propper, David J.

Published
2020
Full Text
View/download PDF

8. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Author

Suárez, Cristina, primary, Larkin, James M.G., additional, Patel, Poulam, additional, Valderrama, Begoña P., additional, Rodriguez-Vida, Alejo, additional, Glen, Hilary, additional, Thistlethwaite, Fiona, additional, Ralph, Christy, additional, Srinivasan, Gopalakrishnan, additional, Mendez-Vidal, Maria Jose, additional, Hartmaier, Ryan, additional, Markovets, Aleksandra, additional, Prendergast, Aaron, additional, Szabados, Bernadett, additional, Mousa, Kelly, additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

9. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Author

Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, and Castellano, Daniel

Published
2020
Full Text
View/download PDF

10. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial

Author

Tan, Wei Shen, primary, Prendergast, Aaron, additional, Ackerman, Charlotte, additional, Yogeswaran, Yathushan, additional, Cresswell, Joanne, additional, Mariappan, Paramananthan, additional, Phull, Jaspal, additional, Hunter-Campbell, Paul, additional, Lazarowicz, Henry, additional, Mishra, Vibhash, additional, Rane, Abhay, additional, Davies, Melissa, additional, Warburton, Hazel, additional, Cooke, Peter, additional, Mostafid, Hugh, additional, Wilby, Daniel, additional, Mills, Robert, additional, Issa, Rami, additional, and Kelly, John D., additional

Published
2022
Full Text
View/download PDF

11. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Author

MSD, Roche, BMS College of Engineering, Pfizer, Novartis, Astellas Pharma, Johnson & Johnson Services, Exelixis, Clovis, Seattle Genetics, AstraZeneca, Merck & Co, Szabados, Bernadett, Kockx, Mark, Assaf, Zoe June, Dam, Pieter-Jan van, Rodriguez-Vida, Alejo, Durán, Ignacio, Crabb, Simon J., Heijden, Michiel S. van der, Font Pous, Albert, Gravis, Gwenaelle, Anido Herranz, Urbano, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Méndez, María José, Suárez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Stanoeva, Diana, Daelemans, Sofie, Rombouts, Miche, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Sharma, Shruti, Aleshin, Alexey, Banchereau, Romain, Castellano-Castillo, Daniel, Powles, Thomas, MSD, Roche, BMS College of Engineering, Pfizer, Novartis, Astellas Pharma, Johnson & Johnson Services, Exelixis, Clovis, Seattle Genetics, AstraZeneca, Merck & Co, Szabados, Bernadett, Kockx, Mark, Assaf, Zoe June, Dam, Pieter-Jan van, Rodriguez-Vida, Alejo, Durán, Ignacio, Crabb, Simon J., Heijden, Michiel S. van der, Font Pous, Albert, Gravis, Gwenaelle, Anido Herranz, Urbano, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Méndez, María José, Suárez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Stanoeva, Diana, Daelemans, Sofie, Rombouts, Miche, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Sharma, Shruti, Aleshin, Alexey, Banchereau, Romain, Castellano-Castillo, Daniel, and Powles, Thomas

Abstract

[Background] Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC)., [Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA) in the ABACUS trial., [Design, setting, and participants] ABACUS was a multicenter, single-arm, neoadjuvant, phase 2 trial, including patients with MIBC (T2-4aN0M0) who were ineligible for or refused neoadjuvant cisplatin-based chemotherapy., [Intervention] Two cycles of atezolizumab were given prior to radical cystectomy. Serial tissue and blood samples were collected., [Outcome measurements and statistical analysis] The primary endpoints of pathological complete response (pCR) rate and dynamic changes to T-cell biomarkers were published previously. Secondary outcomes were 2-yr DFS and OS. A biomarker analysis correlated with relapse-free survival (RFS) was performed, which includes FOXP3, major histocompatibility complex class I, CD8/CD39, and sequential ctDNA measurements., [Results and limitations] The median follow-up time was 25 mo (95% confidence interval [CI] 25–26). Ninety-five patients received at least one cycle of atezolizumab. Eight patients did not undergo cystectomy (only one due to disease progression). The pCR rate was 31% (27/88; 95% CI 21–41). Two-year DFS and OS were 68% (95% CI 58–76) and 77% (95% CI 68–85), respectively. Two-year DFS in patients achieving a pCR was 85% (95% CI 65–94). Baseline PD-L1 and tumor mutational burden did not correlate with RFS (hazard ratio [HR] 0.60 [95% CI 0.24–1.5], p = 0.26, and 0.72 [95% CI 0.31–1.7], p = 0.46, respectively). RFS correlated with high baseline stromal CD8+ (HR 0.25 [95% CI 0.09–0.68], p = 0.007) and high post-treatment fibroblast activation protein (HR 4.1 [95% CI 1.3–13], p = 0.01). Circulating tumor DNA positivity values at baseline, after neoadjuvant therapy, and after surgery were 63% (25/40), 47% (14/30), and 14% (five/36), respectively. The ctDNA status was highly prognostic at all time points. No relapses were observed in ctDNA-negative patients at baseline and after neoadjuvant therapy. The lack of randomization and exploratory nature of the biomarker analysis are limitations of this work., [Conclusions] Neoadjuvant atezolizumab in MIBC is associated with clinical responses and high DFS. CD8+ expression and serial ctDNA levels correlated with outcomes, and may contribute to personalized therapy in the future, [Patient summary] We showed that bladder cancer patients receiving immunotherapy followed by cystectomy have good long-term outcomes. Furthermore, we found that certain biological features can predict patients who might have particular benefit from this therapy.

Published
2022

12. GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen.

Author

Ng, Kenrick, primary, Prendergast, Aaron, additional, Carter, Abigail, additional, Yogeswaran, Yathushan, additional, Alexander, Susanna B., additional, Rudman, Sarah, additional, Wong, Han Hsi, additional, Alifrangis, Constantine, additional, Nowosinska, Ewa, additional, Berney, Daniel, additional, and Shamash, Jonathan, additional

Published
2022
Full Text
View/download PDF

13. Dynamic changes of PD-L1 and T-cell activation in ECLIPSE : A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer

Author

Schmid, Peter, Kockx, Mark, Kim, Sung-Bae, Wheatley, Duncan, Phillips, Melissa Mary, Hoffmann, Oliver, Blohmer, Jens U., Im, Seock-Ah, Schneeweiss, Andreas, Zamora, Esther, Waumans, Yannick, Van Dam, Pieter-Jan, Peeters, Dieter, Wimalasingham, Akhila, Marosics, Patricia, Prendergast, Aaron, Mousa, Kelly, Cortes, Javier, and Kuemmel, Sherko

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2021

14. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Author

Queen Mary University of London, Roche, Cancer Research UK, Experimental Cancer Medicine Centres (UK), Szabados, Bernadett, Rodríguez-Vida, Alejo, Durán, Ignacio, Crabb, Simon J., Heijden, Michiel S. van der, Font Pous, Albert, Gravis, Gwenaelle, Anido Herranz, Urbano, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Méndez, María José, Suárez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Mousa, Kelly, Castellano-Castillo, Daniel, Powles, Thomas, Queen Mary University of London, Roche, Cancer Research UK, Experimental Cancer Medicine Centres (UK), Szabados, Bernadett, Rodríguez-Vida, Alejo, Durán, Ignacio, Crabb, Simon J., Heijden, Michiel S. van der, Font Pous, Albert, Gravis, Gwenaelle, Anido Herranz, Urbano, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Méndez, María José, Suárez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Mousa, Kelly, Castellano-Castillo, Daniel, and Powles, Thomas

Abstract

[Background] There are limited data on toxicity and surgical safety associated with neoadjuvant programmed death ligand 1 (PD-L1) inhibitors prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC)., [Objective] To present a comprehensive safety analysis of the largest neoadjuvant series, with focus on timing and severity of toxicity and surgical complications occurring after neoadjuvant atezolizumab in patients with MIBC enrolled in the ABACUS trial., [Design, setting, and participants] ABACUS (NCT02662309) is an open-label, multicenter, phase II trial for patients with histologically confirmed (T2-T4aN0M0) MIBC, awaiting RC. Patients either were ineligible or refused cisplatin-based neoadjuvant chemotherapy., [Intervention] Two cycles of neoadjuvant atezolizumab (1200 mg, every 3 wk) followed by RC., [Outcome measurements and statistical analysis] Description of atezolizumab toxicity profile in the neoadjuvant setting, impact on surgery, and delayed immune-mediated adverse events (AEs) were assessed., [Results and limitations] Ninety-five patients received treatment. Of them, 44% (42/95) had atezolizumab-related AEs during the neoadjuvant period (fatigue [20%], decreased appetite [6%], and transaminases increased [6%]). Treatment-related grade 3–5 AEs occurred in 11% (10/95) of patients during the study. Of the patients, 21% (20/95) received only one cycle of atezolizumab due to AEs; 92% (87/95) underwent RC. No surgery was delayed due to atezolizumab-related toxicities. Surgical complications occurred in 62% (54/87) of patients. Of these patients, 43% (37/87) and 20% (17/87) had minor (grade 1–2) and major (grade 3–5) complications, respectively. Thirteen of 87 (15%) patients had post-RC atezolizumab-related AEs, including adrenal insufficiency and transaminases increased. Three deaths occurred during the period of study-related interventions (one non–treatment-related aspiration pneumonia, one immune-related myocardial infarction, and one cardiogenic shock after RC). Not all surgical safety parameters were available., [Conclusions] Two cycles of neoadjuvant atezolizumab are well tolerated and do not seem to impact surgical complication rates. Owing to the long half-life, AEs may occur in the postoperative period, including endocrine abnormalities requiring attention and intervention., [Patient summary] Here, we report a comprehensive dataset of patients receiving neoadjuvant immune checkpoint inhibitors before radical cystectomy. Treatment with neoadjuvant atezolizumab is safe and does not seem to complicate surgery significantly.

Published
2021

15. Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

Author

Suarez Rodriguez, Cristina, primary, Larkin, James, additional, Patel, Poulam M., additional, Valderrama, Begoña P., additional, Rodriguez-Vida, Alejo, additional, Glen, Hilary, additional, Thistlethwaite, Fiona, additional, Ralph, Christy, additional, Srinivasan, Gopalakrishnan, additional, Mendez-Vidal, Maria Jose, additional, Carter, Abigail, additional, Tyson, Charlotte, additional, Prendergast, Aaron, additional, Mousa, Kelly, additional, and Powles, Thomas, additional

Published
2021
Full Text
View/download PDF

16. Outcomes of the RAFT trial: robotic surgery after focal therapy

Author

Cathcart, Paul, primary, Ribeiro, Luis, additional, Moore, Caroline, additional, Ahmed, Hashim U., additional, Leslie, Tom, additional, Arya, Manit, additional, Orczyk, Clement, additional, Hindley, Richard G., additional, Cahill, Fidelma, additional, Prendergast, Aaron, additional, Coetzee, Carike, additional, Yogeswaran, Yathushan, additional, Tunna, Kirsty, additional, Sooriakumaran, Prasanna, additional, and Emberton, Mark, additional

Published
2021
Full Text
View/download PDF

17. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study

Author

Cross, Amanda J, Wooldrage, Kate, Robbins, Emma C, Kralj-Hans, Ines, MacRae, Eilidh, Piggott, Carolyn, Stenson, Iain, Prendergast, Aaron, Patel, Bhavita, Pack, Kevin, Howe, Rosemary, Swart, Nicholas, Snowball, Julia, Duffy, Stephen W, Morris, Stephen, Von Wagner, Christian, Halloran, Stephen P, Atkin, Wendy S, Cross, Amanda J [0000-0002-0893-2377], Apollo - University of Cambridge Repository, Cancer Research UK, and Department of Health

Subjects
Adenoma, Male, Gastroenterology & Hepatology, Cost-Benefit Analysis, Colonic Polyps, 1103 Clinical Sciences, colorectal cancer, Colonoscopy, Health Care Costs, Middle Aged, Sensitivity and Specificity, England, Predictive Value of Tests, Occult Blood, Population Surveillance, surveillance, 1114 Paediatrics and Reproductive Medicine, Humans, Female, Colorectal Neoplasms, False Negative Reactions, stool markers, Early Detection of Cancer, Aged
Abstract

OBJECTIVE: The English Bowel Cancer Screening Programme (BCSP) recommends 3 yearly colonoscopy surveillance for patients at intermediate risk of colorectal cancer (CRC) postpolypectomy (those with three to four small adenomas or one ≥10 mm). We investigated whether faecal immunochemical tests (FITs) could reduce surveillance burden on patients and endoscopy services. DESIGN: Intermediate-risk patients (60-72 years) recommended 3 yearly surveillance were recruited within the BCSP (January 2012-December 2013). FITs were offered at 1, 2 and 3 years postpolypectomy. Invitees consenting and returning a year 1 FIT were included. Participants testing positive (haemoglobin ≥40 µg/g) at years one or two were offered colonoscopy early; all others were offered colonoscopy at 3 years. Diagnostic accuracy for CRC and advanced adenomas (AAs) was estimated considering multiple tests and thresholds. We calculated incremental costs per additional AA and CRC detected by colonoscopy versus FIT surveillance. RESULTS: 74% (5938/8009) of invitees were included in our study having participated at year 1. Of these, 97% returned FITs at years 2 and 3. Three-year cumulative positivity was 13% at the 40 µg/g haemoglobin threshold and 29% at 10 µg/g. 29 participants were diagnosed with CRC and 446 with AAs. Three-year programme sensitivities for CRC and AAs were, respectively, 59% and 33% at 40 µg/g, and 72% and 57% at 10 µg/g. Incremental costs per additional AA and CRC detected by colonoscopy versus FIT (40 µg/g) surveillance were £7354 and £180 778, respectively. CONCLUSIONS: Replacing 3 yearly colonoscopy surveillance in intermediate-risk patients with annual FIT could reduce colonoscopies by 71%, significantly cut costs but could miss 30%-40% of CRCs and 40%-70% of AAs. TRIAL REGISTRATION NUMBER: ISRCTN18040196; Results.

Published
2020
Full Text
View/download PDF

18. Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer

Author

Schmid, Peter, primary, Kockx, Mark, additional, Kim, Sung-Bae, additional, Wheatley, Duncan, additional, Phillips, Melissa Mary, additional, Hoffmann, Oliver, additional, Blohmer, Jens U., additional, Im, Seock-Ah, additional, Schneeweiss, Andreas, additional, Zamora, Esther, additional, Waumans, Yannick, additional, Van Dam, Pieter-Jan, additional, Peeters, Dieter, additional, Wimalasingham, Akhila, additional, Marosics, Patricia, additional, Prendergast, Aaron, additional, Mousa, Kelly, additional, Cortes, Javier, additional, and Kuemmel, Sherko, additional

Published
2021
Full Text
View/download PDF

19. Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer

Author

Schmid, Peter, primary, Abraham, Jacinta, additional, Chan, Stephen, additional, Brunt, Adrian Murray, additional, Nemsadze, Gia, additional, Baird, Richard D, additional, Park, Yeon Hee, additional, Hall, Peter, additional, Perren, Timothy, additional, Stein, Robert C, additional, Mangel, László, additional, Ferrero, Jean-Marc, additional, Phillips, Melissa, additional, Conibear, John, additional, Cortes, Javier, additional, Foxley, Andrew, additional, de Bruin, Elza, additional, McEwen, Robert, additional, Nikolaou, Myria, additional, Stetson, Daniel, additional, Dougherty, Brian, additional, Prendergast, Aaron, additional, McLaughlin-Callan, Max, additional, Burgess, Matthew, additional, Lawrence, Cheryl, additional, Cartwright, Hayley, additional, Mousa, Kelly, additional, Turner, Nicholas, additional, and Wheatley, Duncan, additional

Published
2021
Full Text
View/download PDF

20. STARPAC clinical trial

Author

Kocher, Hemant M., primary, Basu, Bristi, additional, Froeling, Fieke EM., additional, Sarker, Debashis, additional, Slater, Sarah, additional, Carlin, Dominic, additional, deSouza, Nandita M., additional, De Paepe, Katja N., additional, Goulart, Michelle R., additional, Hughes, Christine, additional, Imrali, Ahmet, additional, Roberts, Rhiannon, additional, Pawula, Maria, additional, Houghton, Richard, additional, Lawrence, Cheryl, additional, Yogeswaran, Yathushan, additional, Mousa, Kelly, additional, Coetzee, Carike, additional, Sasieni, Peter, additional, Prendergast, Aaron, additional, and Propper, David J., additional

Published
2020
Full Text
View/download PDF

21. MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.

Author

Szabados, Bernadett, primary, Kockx, Mark, additional, Van Dam, Pieter-Jan, additional, Rodriguez-Vida, Alejo, additional, Duran, Ignacio, additional, Crabb, Simon J., additional, Van Der Heijden, Michiel Simon, additional, Font, Albert, additional, Gravis, Gwenaelle, additional, Prendergast, Aaron, additional, Perdicchio, Maurizio, additional, Stanoeva, Diana, additional, Daelemans, Sofie, additional, Mariathasan, Sanjeev, additional, Tea, Joy S., additional, Mousa, Kelly, additional, Banchereau, Romain, additional, Castellano, Daniel, additional, and Powles, Thomas, additional

Published
2020
Full Text
View/download PDF

22. Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.

Author

Suarez Rodriguez, Cristina, primary, Larkin, James M. G., additional, Patel, Poulam, additional, Valderrama, Begona Pérez, additional, Rodriguez-Vida, Alejo, additional, Glen, Hilary, additional, Thistlethwaite, Fiona, additional, Ralph, Christy, additional, Srinivasan, Gopalakrishnan, additional, Mendez Vidal, Maria Jose José, additional, Carter, Abigail, additional, Tyson, Charlotte, additional, Prendergast, Aaron, additional, Mousa, Kelly, additional, and Powles, Thomas, additional

Published
2020
Full Text
View/download PDF

23. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Author

Schmid, Peter, primary, Abraham, Jacinta, additional, Chan, Stephen, additional, Wheatley, Duncan, additional, Brunt, Adrian Murray, additional, Nemsadze, Gia, additional, Baird, Richard D., additional, Park, Yeon Hee, additional, Hall, Peter S., additional, Perren, Timothy, additional, Stein, Robert C., additional, Mangel, László, additional, Ferrero, Jean-Marc, additional, Phillips, Melissa, additional, Conibear, John, additional, Cortes, Javier, additional, Foxley, Andrew, additional, de Bruin, Elza C., additional, McEwen, Robert, additional, Stetson, Daniel, additional, Dougherty, Brian, additional, Sarker, Shah-Jalal, additional, Prendergast, Aaron, additional, McLaughlin-Callan, Max, additional, Burgess, Matthew, additional, Lawrence, Cheryl, additional, Cartwright, Hayley, additional, Mousa, Kelly, additional, and Turner, Nicholas C., additional

Published
2020
Full Text
View/download PDF

24. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

Author

Schmid, Peter, primary, Zaiss, Matthias, additional, Harper-Wynne, Catherine, additional, Ferreira, Marta, additional, Dubey, Sidharth, additional, Chan, Stephen, additional, Makris, Andreas, additional, Nemsadze, Gia, additional, Brunt, Adrian M., additional, Kuemmel, Sherko, additional, Ruiz, Isabel, additional, Perelló, Antonia, additional, Kendall, Anne, additional, Brown, Janet, additional, Kristeleit, Hartmut, additional, Conibear, John, additional, Saura, Cristina, additional, Grenier, Julien, additional, Máhr, Károly, additional, Schenker, Michael, additional, Sohn, Joohyuk, additional, Lee, Keun Seok, additional, Shepherd, Christopher J., additional, Oelmann, Elisabeth, additional, Sarker, Shah-Jalal, additional, Prendergast, Aaron, additional, Marosics, Patricia, additional, Moosa, Atiyyah, additional, Lawrence, Cheryl, additional, Coetzee, Carike, additional, Mousa, Kelly, additional, and Cortés, Javier, additional

Published
2019
Full Text
View/download PDF

25. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).

Author

Powles, Thomas, primary, Larkin, James M. G., additional, Patel, Poulam, additional, Pérez-Valderrama, Begoña, additional, Rodriguez-Vida, Alejo, additional, Glen, Hilary, additional, Thistlethwaite, Fiona, additional, Ralph, Christy, additional, Srinivasan, Gopalakrishnan, additional, Mendez-Vidal, Maria Jose, additional, Liu, Wing-Kin, additional, Prendergast, Aaron, additional, Vosper, Laura, additional, Mousa, Kelly, additional, and Suárez, Cristina, additional

Published
2019
Full Text
View/download PDF

26. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study

Author

Atkin, Wendy, primary, Cross, Amanda J, additional, Kralj-Hans, Ines, additional, MacRae, Eilidh, additional, Piggott, Carolyn, additional, Pearson, Sheena, additional, Wooldrage, Kate, additional, Brown, Jeremy, additional, Lucas, Fiona, additional, Prendergast, Aaron, additional, Marchevsky, Natalie, additional, Patel, Bhavita, additional, Pack, Kevin, additional, Howe, Rosemary, additional, Skrobanski, Hanna, additional, Kerrison, Robert, additional, Swart, Nicholas, additional, Snowball, Julia, additional, Duffy, Stephen W, additional, Morris, Stephen, additional, von Wagner, Christian, additional, and Halloran, Stephen, additional

Published
2019
Full Text
View/download PDF

27. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study

Author

Cross, Amanda J, primary, Wooldrage, Kate, additional, Robbins, Emma C, additional, Kralj-Hans, Ines, additional, MacRae, Eilidh, additional, Piggott, Carolyn, additional, Stenson, Iain, additional, Prendergast, Aaron, additional, Patel, Bhavita, additional, Pack, Kevin, additional, Howe, Rosemary, additional, Swart, Nicholas, additional, Snowball, Julia, additional, Duffy, Stephen W, additional, Morris, Stephen, additional, von Wagner, Christian, additional, Halloran, Stephen P, additional, and Atkin, Wendy S, additional

Published
2018
Full Text
View/download PDF

28. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Author

Powles, Thomas, primary, Rodriguez-Vida, Alejo, additional, Duran, Ignacio, additional, Crabb, Simon J., additional, Van Der Heijden, Michiel Simon, additional, Font Pous, Albert, additional, Gravis, Gwenaelle, additional, Anido Herranz, Urbano, additional, Protheroe, Andrew, additional, Ravaud, Alain, additional, Maillet, Denis, additional, Mendez-Vidal, Maria Jose, additional, Suarez, Cristina, additional, Lorch, Anja, additional, Sternberg, Cora N., additional, Linch, Mark David, additional, Sarker, Shah-Jalal, additional, Prendergast, Aaron, additional, Mousa, Kelly, additional, and Castellano, Daniel E., additional

Published
2018
Full Text
View/download PDF

29. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Author

Schmid, Peter, primary, Abraham, Jacinta, additional, Chan, Stephen, additional, Wheatley, Duncan, additional, Brunt, Murray, additional, Nemsadze, Gia, additional, Baird, Richard, additional, Park, Yeon Hee, additional, Hall, Peter, additional, Perren, Timothy, additional, Stein, Robert C., additional, László, Mangel, additional, Ferrero, Jean-Marc, additional, Phillips, Melissa, additional, Conibear, John, additional, Sarker, Shah-Jalal, additional, Prendergast, Aaron, additional, Cartwright, Hayley, additional, Mousa, Kelly, additional, and Turner, Nicholas C., additional

Published
2018
Full Text
View/download PDF

30. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.

Author

Cross, Amanda J., Wooldrage, Kate, Robbins, Emma C., Kralj-Hans, Ines, MacRae, Eilidh, Piggott, Carolyn, Stenson, Iain, Prendergast, Aaron, Patel, Bhavita, Pack, Kevin, Howe, Rosemary, Swart, Nicholas, Snowbal, Julia, Duffy, Stephen W., Morris, Stephen, von Wagner, Christian, Halloran, Stephen P., and Atkin, Wendy S.

Subjects
FECAL occult blood tests, POLYPECTOMY, ADENOMATOUS polyps, MEDICAL sciences, ENDOSCOPIC ultrasonography, VIRTUAL colonoscopy
Published
2019
Full Text
View/download PDF

31. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Author

Carike Coetzee, Hemant M. Kocher, Debashis Sarker, Yathushan Yogeswaran, Christine Hughes, Richard Houghton, Aaron Prendergast, Cheryl Lawrence, Peter Sasieni, Dominic Carlin, Katja N. De Paepe, Sarah Slater, David Propper, Michelle R. Goulart, Kelly Mousa, Maria Pawula, Ahmet Imrali, Fieke E. M. Froeling, Nandita M. deSouza, Bristi Basu, Rhiannon Roberts, Kocher, Hemant M. [0000-0001-6771-1905], Basu, Bristi [0000-0002-3562-2868], Carlin, Dominic [0000-0002-1783-412X], Goulart, Michelle R. [0000-0001-8333-3908], Imrali, Ahmet [0000-0003-3661-9932], Yogeswaran, Yathushan [0000-0002-5220-9135], Coetzee, Carike [0000-0002-4933-1279], Sasieni, Peter [0000-0003-1509-8744], Prendergast, Aaron [0000-0002-9668-6689], Propper, David J. [0000-0002-4274-5460], Apollo - University of Cambridge Repository, Kocher, Hemant M [0000-0001-6771-1905], Goulart, Michelle R [0000-0001-8333-3908], and Propper, David J [0000-0002-4274-5460]

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, 692/4028/67/1504/1713, Maximum Tolerated Dose, Receptors, Retinoic Acid, medicine.medical_treatment, Science, Population, 692/4020/1503/1712/1713, General Physics and Astronomy, Phases of clinical research, Tretinoin, 692/308/2779/109/1940, Fatty Acid-Binding Proteins, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Phase I trials, Pancreatic cancer, Internal medicine, medicine, Carcinoma, Biomarkers, Tumor, Humans, lcsh:Science, education, neoplasms, Chemotherapy, education.field_of_study, Multidisciplinary, business.industry, organic chemicals, article, General Chemistry, medicine.disease, biological factors, Clinical trial, Pancreatic Neoplasms, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Pharmacodynamics, lcsh:Q, business, Carcinoma, Pancreatic Ductal
Abstract

Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma (PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients with advanced, unresectable PDAC (n = 27), ATRA is re-purposed as a stromal-targeting agent in combination with gemcitabine-nab-paclitaxel chemotherapy using a two-step adaptive continual re-assessment method trial design. The maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D, primary outcome) is the FDA/EMEA approved dose of gemcitabine-nab-paclitaxel along-with ATRA (45 mg/m2 orally, days 1–15/cycle). Dose limiting toxicity (DLT) is grade 4 thrombocytopenia (n = 2). Secondary outcomes show no detriment to ATRA pharmacokinetics.. Median overall survival for RP2D treated evaluable population, is 11.7 months (95%CI 8.6–15.7 m, n = 15, locally advanced (2) and metastatic (13)). Exploratory pharmacodynamics studies including changes in diffusion-weighted (DW)-MRI measured apparent diffusion coefficient after one cycle, and, modulation of cycle-specific serum pentraxin 3 levels over various cycles indicate stromal modulation. Baseline stromal-specific retinoid transport protein (FABP5, CRABP2) expression may be predicitve of response. Re-purposing ATRA as a stromal-targeting agent with gemcitabine-nab-paclitaxel is safe and tolerable. This combination will be evaluated in a phase II randomized controlled trial for locally advanced PDAC. Clinical trial numbers: EudraCT: 2015-002662-23; NCT03307148. Trial acronym: STARPAC., All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment for patients with advanced pancreatic cancer, and demonstrate a stromal modulatory effect.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results